で公開中です！詳しく見る

Quest Diagnostics

DGX

時価総額 $259億

235.00 USD

-4.15

1.74%

終値時点更新済み 10月16日 16:00 EDT

プレマーケット

時間外取引

235.00

0.00

0%

1日

-1.74%

5日間

2.77%

1か月

-4.89%

3か月

12.22%

6か月

22.74%

年初来

35.22%

1年

25.79%

5年間

63.51%

10年間

183%

概要： Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the US. The company generates over 97% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,400 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.

従業員数： 57,000

ヘルスケア診断・リサーチ

ニュース

ポジティブ

ニュートラル

ネガティブ

センチメント 3か月間

ポジティブ 53.6%

ニュートラル 42.9%

ネガティブ 3.6%

ニュートラル

Dividend Champion, Contender, And Challenger Highlights: Week Of October 18

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies that changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of October 18

ニュートラル

Zacks Investment Research

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

DGX heads into Q3 earnings with expected revenue and EPS growth, fueled by strong clinical demand, advanced diagnostics and operational efficiencies.

Here's How Quest Diagnostics Is Placed Ahead of Q3 Earnings

ポジティブ

Zacks Investment Research

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Quest Diagnostics (DGX) is a Strong Value Stock

ニュートラル

Dividend Champion, Contender, And Challenger Highlights: Week October 4

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week October 4

ニュートラル

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

Test showed 100% specificity, with no false-positive results in the cohort, at both 3- and 5-year follow-up, and sensitivity of 100% and 83.3%, respectively, for predicting disease recurrence SECAUCUS, N.J., Oct. 1, 2026 /PRNewswire/ -- A new study published in The Journal of Molecular Diagnostics showed that the Haystack MRD® test is highly accurate at detecting residual and recurrent disease, demonstrating clinical performance in specimens from the landmark DYNAMIC colorectal cancer trial series.

Haystack MRD® Demonstrates Robust Clinical Performance in Specimen Cohort from the Landmark DYNAMIC Colorectal Cancer Trials

ポジティブ

Zacks Investment Research

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

DGX's 36.3% YTD rise reflects momentum in advanced diagnostics, channel growth, AI adoption and cost savings.

Quest Diagnostics Stock Gains 36.3% YTD: What's Behind the Rally?

ポジティブ

Zacks Investment Research

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term

ポジティブ

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

Quest Diagnostics Incorporated's recurring testing demand provides a foundation for growth through hospital partnerships, dialysis services, and advanced diagnostics. Their dialysis testing and advanced diagnostics add growth opportunities, although their value ultimately depends on execution and reimbursement. So far, DGX's cash flows seem to be benefiting from the acquisition strategy, but if this falters, it may lead to write-downs of its sizable goodwill on the balance sheet.

Quest Diagnostics Incorporated: Testing Growth Keeps Me Bullish Despite Medicare Headwinds

ニュートラル

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

SECAUCUS, N.J., Sept. 22, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its third quarter 2026 financial results on Thursday, October 22, 2026, before the market opens.

Quest Diagnostics to Release Third Quarter Financial Results on October 22, 2026

ネガティブ

The Motley Fool

Why Quest Diagnostics Holdings Stock Dropped Today

Medicare and Medicaid have been overpaying Quest Diagnostics for years, says the government. Starting next year, they plan to cut reimbursement of lab testing by 15%.

Why Quest Diagnostics Holdings Stock Dropped Today

ニュースランキングを見る

価格チャートは Lightweight Charts™ を使用して実装されています